India’s pharmaceutical industry is advancing toward high-science, innovation-driven Active Pharmaceutical Ingredient (API) development as HRV Pharma and Shodhana Laboratories announced a strategic multi-year Contract Development and Manufacturing (CDMO) partnership to accelerate next-generation API development.
The collaboration integrates HRV Pharma’s AI-enabled virtual API platform, regulatory expertise, and global market access with Shodhana Laboratories’ strengths in process chemistry, high-purity synthesis, and GMP-compliant manufacturing. This partnership aims to create a seamless pathway from early-stage development to global commercialization of complex pharmaceutical ingredients.
Advancing High-Science API Development
Under the agreement announced on March 30, 2026, both companies will co-develop a pipeline of high-value APIs targeting emerging therapeutic areas such as precision medicine, longevity biology, oncology supportive care, and neurodegenerative conditions.
A key milestone includes the development and filing of a US Drug Master File (DMF) for a pharmaceutical-grade API associated with cellular energy, DNA repair, and ageing processes. This positions HRV Pharma as the holder of the first active Indian DMF in this specific API category, marking a significant advancement in regulated pharmaceutical manufacturing.
Integrated Development and Manufacturing Capabilities
The partnership combines digital innovation with advanced chemistry capabilities to deliver end-to-end API solutions. HRV Pharma contributes its virtual API platform, global regulatory management, and access to markets across 50+ countries, while Shodhana provides deep expertise in synthesis precision and large-scale GMP manufacturing infrastructure.
Together, both companies will execute:
- Development and regulatory filing of pharmaceutical-grade APIs
- End-to-end GMP manufacturing, validation, and stability studies
- Global regulatory submissions across the US, Europe, LATAM, MENA, and APAC
- A unified compliance and audit-ready framework for regulated markets.
Expanding Pipeline Across Therapeutic Segments
The collaboration includes a pipeline of five advanced APIs spanning central nervous system (CNS) disorders, rare diseases, metabolic conditions, and neurological therapies. These APIs are being developed with identified end-customers in key markets such as the United States and Europe, reflecting strong global demand for specialized and high-value pharmaceutical ingredients.
The structured, milestone-driven execution model is expected to accelerate development timelines while maintaining strict regulatory and quality standards required for international markets.
Enabling Precision Medicine and Future Pharma Trends
This partnership reflects a broader shift in India’s API industry from volume-driven generics manufacturing toward innovation-led, specialty APIs aligned with precision medicine and advanced therapeutics. By leveraging AI-enabled platforms and high-precision manufacturing, the collaboration aims to unlock new opportunities in global pharmaceutical supply chains.
Outlook
The HRV Pharma–Shodhana collaboration, announced on March 30, 2026, highlights the increasing importance of technology-driven partnerships in pharmaceutical manufacturing. As demand for complex and regulated APIs continues to grow, such alliances are expected to play a critical role in shaping the future of global drug development.
By combining digital innovation, regulatory expertise, and advanced manufacturing, both companies are positioning themselves at the forefront of next-generation API development, reinforcing India’s role as a global hub for high-value pharmaceutical production.
